Navigation Links
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008.

As was previously announced, the Phase 2 trial of CERE-120 involving 52 patients, failed to demonstrate a difference in the primary endpoint between patients in the CERE-120 versus control group. It was subsequently announced, however, that CERE-120 suggested improvement on several secondary endpoints at 12 months, and at 18 months, a statistically significant treatment effect on the primary endpoint emerged, while several additional secondary endpoints also showed improvement. In contrast, on no measure did sham patients perform better than CERE-120 patients, at either 12 or 18 months. Based on those findings, and insight gained from analyses of post-mortem brain tissue from two CERE-120 treated patients, the company has revised the dosing regimen and expects to initiate a new trial of CERE-120 in the near future.

"We are pleased to be able to gather unique, long-term data from both CERE-120 treated and control patients and thus gain more information about the potential long-term effects of CERE-120 on Parkinson's disease," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "We very much appreciate the support the MJFF has provided to enable us to expand the testing of these patients and further enrich our data base. Our conviction about CERE-120's potential to treat Parkinson's disease remains strong. We learned a significant amount from the initial Phase 2 trial wh
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
2. Ceregene Announces Two Key Additions to Leadership Team
3. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
6. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
7. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
8. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
9. SyntheMed Receives US Patent on Novel Polymer Technology
10. Sunesis Receives Approval for Listing on The NASDAQ Capital Market
11. Anesiva Receives NASDAQ Delisting Staff Determination Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... CLINTON, N.J. and JERUSALEM, July 6 Ikaria Holdings, ... Ikaria has entered into an agreement to obtain a ... treatment for preventing pathological cardiac remodeling following acute myocardial ... phase I/II clinical trial, is administered via the coronary ...
... /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink ... of nationally branded therapeutic, natural skin and health care ... an agreement with 3PL Worldwide, Inc., for all Order ... CEO explains that "3PL Worldwide offers true multichannel support ...
... July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... the $29.5 million of outstanding 8% Senior Convertible Notes due ... July 1, 2009 is effective as of 8:00 a.m. today. ... with holders of 87% of the Notes, which is above ...
Cached Biology Technology:IKARIA(R) to In-License BioLineRx's BL-1040 2IKARIA(R) to In-License BioLineRx's BL-1040 3avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product 2Verenium Completes Amendment to 8% Senior Convertible Notes 2Verenium Completes Amendment to 8% Senior Convertible Notes 3Verenium Completes Amendment to 8% Senior Convertible Notes 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... the University of Melbourne has used new technology to fast ... could assist in the discovery of other cancer genes. ... of Pathology at the University of Melbourne, who led the ... breast cancer risk gene to be discovered using the latest ...
... release is available in German . Dolphins ... others; on the other hand, they live in an open social ... in the animal kingdom in dolphins in Shark Bay, Australia. ... group behavior of all mammals after us humans. Studies in the ...
... PROVIDENCE, R.I. [Brown University] If the fight against breast ... CBP, and CRM1 would be among the shadier figures. In ... 30 Journal of Biological Chemistry is the police ... alive: survivin,s jailbreak from the nucleus, aided and abetted by ...
Cached Biology News:Breast cancer risk gene discovery fast tracked by new technology 2Dolphins cultivate loose alliances 2Protein 'jailbreak' helps breast cancer cells live 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: